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Time to go functional! Determining tumors’ DNA repair capacity 
ex vivo
Manuela Tumiati, Sakari Hietanen and Liisa Kauppi
The ability to better predict response to cancer 
therapy would substantially improve the lives of 
patients. For high-grade serous ovarian cancer (HGSOC) 
tumors, their DNA repair capacity - via the homologous 
recombination (HR) pathway - is the most important 
molecular determinant of sensitivity to platinum 
compounds, the DNA-damaging chemotherapy used in 
first-line treatment [1]. Namely, HR-deficient tumors are 
platinum sensitive.
To date, approaches to identify HGSOC patients 
with HR-deficient tumors have relied largely on DNA 
sequencing. They are based on scoring deleterious 
mutations in BRCA1, BRCA2 and other known HR genes 
and/or identifying features of the genomic landscape, that 
is, so-called genomic scars and mutational signatures 
associated with HR deficiency. These methods carry 
limitations, however. First, HR deficiency caused by 
epigenetic alterations (e.g. BRCA1 promoter methylation) 
is not detected by mutation screening. Second, mutations 
of uncertain significance may or may not confer HR 
deficiency. Third, genomic scars and mutational signatures 
associated with HR deficiency do not necessarily 
correspond to functional HR deficiency - HR-reversion 
mutations have been shown to restore HR functionality 
in tumor cells, while the “historical” genomic signature 
of HR deficiency is retained. Moreover, high-throughput 
sequencing remains comparatively expensive and 
necessitates heavy downstream bioinformatic analyses. 
Thus, it is not suited for determining tumors’ HR capacity 
at the time when the sample is collected in surgery, nor in 
a routine clinical laboratory setting with limited resources. 
Limitations of DNA sequence-based testing can be 
overcome by directly assessing whether the HR pathway is 
functional. To this end, detecting nuclear foci of RAD51, 
the key HR recombinase, has proven a powerful technique 
in classifying HR-deficient versus HR-proficient breast 
cancer samples [2, 3]. We set out to adapt this approach for 
HGSOC samples, and to validate its utility in predicting 
clinical platinum sensitivity. We obtained an HR score 
for each HGSOC patient sample by quantifying RAD51-
mediated repair after ionizing radiation (IR) induced DNA 
damage in primary cell culture [4]. HGSOC samples 
clustered into three functional groups: HR-deficient, 
HR-low and HR-proficient (Figure 1A); genomic 
characteristics of HR deficiency were absent in one quarter 
of HR-deficient and HR-low samples. Low HR scores 
significantly correlated with platinum sensitivity, longer 
platinum-free interval and improved overall survival.
              Editorial
Figure 1: HR scores, as assessed by functional ex vivo testing, from 21 HGSOC patients (A, data from ref. 4) and 17 
TNBC patients (B, data from ref. 5). Dashed lines indicate thresholds for the three HR capacity categories, as defined in the two studies. 
Asterisks in B mark the position of two TNBC samples with an HR score of zero [5].
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Shortly after our HGSOC study, Dik van Gent’s 
group published a comprehensive analysis of HR 
capacity, as determined by RAD51 positivity ex vivo 
after IR-induced DNA damage, in 170 primary breast 
cancers [5]. The authors defined three sample groups, HR-
deficient, HR-intermediate and HR-proficient (Figure 1B). 
Consistent with previous studies, HR gene mutations and 
genomic scars only partially associated with functional 
HR deficiency. 
Given that the triple-negative breast cancer 
(TNBC) subtype is molecularly similar to HGSOC [6], 
it is now possible to compare the scope and frequency 
of HR deficiency in HGSOC versus TNBC (Figure 1). 
Interestingly, HR status in TNBC appears bimodal: all 
except one sample can be classified as clearly HR-deficient 
or HR-proficient (Figure 1B). In contrast, HR scores 
of HGSOC samples form a continuum, and the most 
common category in our cohort was low-proficiency HR 
(Figure 1A). This presumably reflects higher heterogeneity 
in HGSOC tumors compared to TNBC, and carries the 
implication of more varied long-term responses to DNA-
damaging chemotherapy in HGSOC.
Another facet of HGSOC tumor heterogeneity 
uncovered in our study was that different anatomical 
sites within a single patient displayed a wide range of 
HR capacity. Of the five locations sampled at the time of 
surgery, one tumor (omentum) was HR-deficient, three 
tumors (left ovary, ascites and peritoneum) were HR-low 
and one (right ovary) was HR-proficient, resulting in an 
average of HR-low classification for this patient [4]. This 
so far anecdotal example highlights the tumor complexity 
that exists in therapy-naïve HGSOC patients. Such 
complexity will likely contribute to relapse events, even 
if primary chemotherapy is successful. It should be taken 
into account when sampling patient tumors for functional 
HR testing; a single anatomical site may not give a reliable 
estimate of HR capacity.
With the emergence of a new class of drugs, 
poly(ADP-ribose) polymerase (PARP) inhibitors in the 
clinic, functional read-outs of HR deficiency in breast and 
ovarian cancer are more important than ever before. For 
the repair of chemotherapy-induced DNA damage, HR-
deficient tumor cells rely heavily on alternative pathways 
that are dependent on PARP activity. Blocking these 
pathways using PARP inhibitors (PARPi) generates a 
synergistic cell-killing effect known as synthetic lethality 
[7]. 
Patients with HR-deficient (that is, platinum-
sensitive) tumors benefit significantly from PARPi 
maintenance therapy [8-10] but so far, methods to 
reliably identify this cohort have been lacking [8]. Ex vivo 
functional HR testing in two poor-prognosis cancer types, 
HGSOC and TNBC, has been now shown to be feasible 
[4, 5]. Determining the molecular phenotype (rather 
than genotype) of platinum-sensitivity will be central in 
comprehensively identifying those cancer patients who 
can benefit from PARPi therapy.
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